ONCAlert | 2018 ASCO Annual Meeting

Melanoma MORE >>

Patients aged ≥62 years with melanoma were more likely to respond to treatment with pembrolizumab than younger patients, according to results published in Clinical Cancer Research. Investigators at The Wistar Institute in Philadelphia concluded that the risk for progression following anti–PD-1 therapy declined by 13% with each decade of life.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.